Allan Gordon, MD, PhD

Allan Gordon, MD, PhD has an extensive work experience in the pharmaceutical and biotechnology industry. Allan is currently serving as the Chief Medical Officer at AnaCardio since September 2021. Prior to that, they held the same position at Carmot Therapeutics, Inc. from January 2020 to December 2020, at AVIVE Pharma from August 2017 to January 2020, and at LymeTek Inc. from October 2018 to July 2019. Before their roles as a Chief Medical Officer, Allan worked as the Vice President Clinical Science at XOMA from July 2015 to August 2017. Allan also served as the SVP Clinical Development at Resverlogix Corporation from February 2008 to March 2014. Furthermore, they were the CEO of Nile Therapeutics Inc. for a brief period in 2007, where they built the office and management, conducted FiM Study, and resigned when the company went public. Allan has also worked as the Senior Director Clinical Development at Scios, Johnson & Johnson, and as a Consultant at AstraZeneca in 2004. Allan began their career as the Medical Director Scandinavia at Bristol-Myers Squibb from January 2000 to May 2003.

Allan Gordon, MD, PhD has an extensive education history. Allan attended Karolinska Institutet from 1981 to 1986, where they earned their MD degree in Medical School. In 1983, they briefly attended Brown University for medical school, although the degree obtained is unspecified.

After completing their MD, Allan Gordon returned to Karolinska Institutet and pursued further studies in Cardiology. From 1992 to 1996, they obtained their Doctor of Philosophy (PhD) degree with a specialization in Cardiology.

Allan continued their academic pursuits at Karolinska Institutet and became an Associate Professor in the field of Cardiology, a position they held from 1996 to 2004.